BioSpace News Archive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

New findings from an American College of Cardiology’s (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around treatment options for heart valve disease (HVD)

BTL, the authority in non-invasive aesthetic and wellness therapies, announced today that nine studies have been accepted for presentation at the 40th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS).

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, reported its financial results for the quarter ended March 31, 2021.

Amneal Pharmaceuticals, Inc. announced that its management team will virtually attend the following investor conferences

Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the closing of its previously announced underwritten public offering of 15,333,332 shares of its common stock

To meet the Biden Administration’s goal of having at least one COVID shot in the arms of 70 percent of Americans by July 4, vaccine hesitancy must be overcome, notes the Association of American Physicians and Surgeons.

Lennham Pharmaceuticals, a clinical-stage start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,000,534 with an expiration date of December 2040.

Deep Lens and Oncology and Hematology Specialists, P.A. today announced that they will partner to deploy artificial-intelligence (AI)-based trial matching solution, VIPER™, into the New Jersey-based cancer network

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that its CEO, Dr. Daniel Teper, will be presenting in the following industry conferences: